Treatment of hematological malignant disorders has been improved over the last years,
but high relapse rate mainly attributable to the presence of minimal residual disease
still persists. Therefore, it is of great interest to explore novel therapeutic strategies
to obtain long-term remission. Immune effector cells, and especially natural killer (NK)
cells, play a crucial role in the control of hematological malignancies. In this regard, the
efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated
graft versus leukemia effect without the risk of inducing graft versus host disease.
Alloreactive donor NK cells generated following hematopoietic stem cell transplantation
ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro
expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell
effector functions against resistant leukemia cells, novel immunotherapeutic strategies are
oriented to the identification, isolation, expansion, and administration of particular NK cell
subsets endowed with multifunctional anti-tumor potential and tropism toward tumor
sites. Moreover, the relationship between the emergence and persistence of distinct
NK cell subsets during post-graft reconstitution and the maintenance of a remission state
is still rather unclear